March 21, 2025

Contaminant Limits Now Searchable, Says FDA

New online tool lists chemical levels in human foods as part of broader federal push to improve transparency and reduce harmful additives.

Reuters

March 19, 2025

Study Shows Widespread Delays in Medical Device Reporting to FDA

Late reporting was concentrated among a small number of manufacturers, with 3 manufacturers and 13 devices accounting for 54.8% of all late reports between 2019 and 2022.

Conexiant

March 18, 2025

U.S. Fertility Rates Continue Decline; Age of Mothers Shifts

Maternal age distribution shifts dramatically as overall birth rates continue a 30-year decline, with women younger than 30 now accounting for less than half of all births, and an increase of older mothers.

Conexiant

March 18, 2025

FDA Approves First Liquid Losartan Formulation

FDA approves Arbli (TM), the first ready-to-use losartan oral suspension for hypertension, stroke risk reduction, and diabetic nephropathy.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 05, 2025

FDA Monthly Round-Up: Key February Updates

February's FDA approvals feature advancements in cardiology, neurology, infectious diseases, and rare disorders, including the first trials for genetically modified pig kidney transplants and novel treatments for Parkinson’s disease and spinal muscular atrophy.

Conexiant

March 03, 2025

More States Fast Track Foreign-Trained Physicians

Since 2023, nine states have waived U.S. residency requirements for some foreign-trained physicians, with more states considering similar changes.

KFF Health News

March 03, 2025

FDA Approves New Hormone-Free Copper IUD

The FDA has approved Miudella, a hormone-free copper IUD, for pregnancy prevention for up to three years, marking the first approval of a new copper IUD in the U.S. in over 40 years.

Conexiant

February 28, 2025

FDA Issues Label Change to Testosterone Drugs

The U.S. FDA has recommended new labeling changes for testosterone products based on clinical and post-market studies related to blood pressure and cardiovascular effects.

Reuters